Tumor expression of Fas ligand (CD95L) and the consequences
- 1 October 1998
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 10 (5) , 564-572
- https://doi.org/10.1016/s0952-7915(98)80225-2
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Fas and FasL in the homeostatic regulation of immune responsesPublished by Elsevier ,2001
- Constitutive Expression of FasL in ThyrocytesScience, 1998
- CD4 Regulates Susceptibility to Fas ligand– and Tumor Necrosis Factor–mediated ApoptosisThe Journal of Experimental Medicine, 1998
- TRANSPLANTATION OF CD95 LIGAND-EXPRESSING GRAFTSTransplantation, 1997
- Requirement of Cell–Cell Contact in the Induction of Jurkat T Cell Apoptosis: The Membrane-Anchored but Not Soluble Form of FasL Can Trigger Anti-CD3-Induced Apoptosis in Jurkat T CellsBiochemical and Biophysical Research Communications, 1997
- ICE-proteases mediate HTLV-I Tax-induced apoptotic T-cell deathOncogene, 1997
- Apoptosis by Death FactorCell, 1997
- Fas Signal Transduction Triggers Either Proliferation or Apoptosis in Human FibroblastsJournal of Investigative Dermatology, 1997
- A role for CD95 ligand in preventing graft rejectionNature, 1995
- Regulation of cell surface APO‐1/Fas (CD95) ligand expression by metalloproteasesEuropean Journal of Immunology, 1995